Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preclinical Evaluation of a Novel TALEN Targeting CCR5 Confirms Efficacy and Safety in Conferring Resistance to HIV‐1 Infection

26 Oct 2020

Abstract excerpt

Therapies to treat patients infected with human immunodeficiency virus (HIV) aim at preventing viral replication but fail to eliminate the virus. Although transplantation of allogeneic CCR5Δ32 homozygous stem cell grafts provided a cure for a few patients, this approach is not considered a general therapeutic strategy because of potential side effects. Conversely, gene editing to disrupt the C-C chemokine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to HIV Research and Treatment
Share to Mosquito-borne diseases and control

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33103367
DOI: 10.1002/biot.202000023

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preclinical Evaluation of a Novel TALEN Targeting CCR5 Confirms Efficacy and Safety in Conferring Resistance to HIV‐1 InfectionPMID 33103367Read ↗

mRNA transfection of a novel TAL effector nuclease (TALEN) facilitates efficient knockout of HIV co-receptor CCR5.Semantic proximity Read ↗

The clinical applications of genome editing in HIVSemantic proximity Read ↗

CCR5-edited gene therapies for HIV cure: Closing the door to viral entry.Semantic proximity Read ↗

The clinical potential of gene editing as a tool to engineer cell‐based therapeuticsSemantic proximity Read ↗

Targeted disruption of the CCR5 gene in human hematopoietic stem cells stimulated by peptide nucleic acids.Semantic proximity Read ↗

CRISPR/Cas9-Mediated CCR5 Ablation in Human Hematopoietic Stem/Progenitor Cells Confers HIV-1 Resistance In Vivo.Semantic proximity Read ↗

Preclinical development and qualification of ZFN-mediated CCR5 disruption in human hematopoietic stem/progenitor cellsSemantic proximity Read ↗

Novel lentiviral vectors with mutated reverse transcriptase for mRNA delivery of TALE nucleases.Semantic proximity Read ↗

Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5.Semantic proximity Read ↗

Efficient modification of <i>CCR5</i> in primary human hematopoietic cells using a megaTAL nuclease and AAV donor templateSemantic proximity Read ↗

High frequency CCR5 editing in human hematopoietic stem progenitor cells protects xenograft mice from HIV infectionSemantic proximity Read ↗

Chemokine receptor 5 knockout strategiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.